Just the beginning

Biotechs never die - they comeback with a vengeance. Watch for a massive re-rating by year end. Negligeable volume (in dollar terms a trader's pittance) with no institutional trader selling. This was factored into current price months ago but what isn't factored is the success in the lab of current and future programs. Weak hands shaken out and the last of the small parcels transferred into the hands of those who know what's coming next.

Over a dollar by Christmas.

Good luck to all holders.